30.07.2013 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces H1/2013 record results, raises 2013 Group earnings guidance


 
Fresenius SE & Co. KGaA / Key word(s): Quarter Results 30.07.2013 06:59 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius announces H1/2013 record results, raises 2013 Group earnings guidance Group sales increased by 8% (9% in constant currency) to EUR9,987 million (H1/2012: EUR9,236 million). Organic sales growth was 5%. Acquisitions contributed a further 5%. Divestitures reduced sales growth by 1%. Group EBIT* increased by 1% (2% in constant currency) to EUR1,448 million (H1/2012: EUR1,440 million). The EBIT margin of 14.5% (H1/2012: 15.6%) was impacted by a margin decrease at Fresenius Medical Care as well as the first-time consolidation of Fenwal. However, Q2/2013 margin of 14.8% already showed a distinct improvement over Q1/2013 (14.2%). Group net income** increased by 11% (12% in constant currency) to EUR482 million (H1/2012: EUR434 million). Group net income attributable to shareholders of Fresenius SE & Co. KGaA including one-time integration costs for Fenwal was EUR462 million or EUR2.59 per share. Based on the Group's positive growth prospects for the second half of 2013, Fresenius raises its full-year earnings guidance. The company now expects net income*** to increase by 11% to 14% in constant currency. Previously, Fresenius expected net income growth of 7% to 12% in constant currency. The company fully confirms its sales guidance. Sales are expected to increase by 7% to 10% in constant currency. * 2013 excluding Fenwal integration costs (EUR27 million). 2012 excluding one-time costs related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR7 million). ** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding Fenwal integration costs (EUR20 million); 2012 excluding a non-taxable investment gain (EUR34 million) as well as one-time costs related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR26 million). *** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding Fenwal integration costs  (~EUR 50 million pre tax); 2012 excluding a non-taxable investment gain (EUR34 million) and other one-time costs at Fresenius Medical Care (EUR17 million) as well as one-time costs related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR29 million). (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., July 30, 2013 End of note 30.07.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 40.840,00 22.299,00
EBITDA1,2 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 6.808,00 3.422,00
EBITDA-Marge3 18,69 17,04 19,01 19,66 18,27 16,67
EBIT1,4 4.589,00 5.251,00 4.631,00 4.385,00 4.158,00 3.321,00 1.143,00
EBIT-Marge5 13,69 14,83 12,43 12,09 11,08 8,13 5,13
Jahresüberschuss1 1.816,00 1.871,00 1.915,00 2.823,00 2.819,00 2.117,00 -594,00
Netto-Marge6 5,42 5,28 5,14 7,78 7,51 5,18 -2,66
Cashflow1,7 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 4.198,00 4.456,00
Ergebnis je Aktie8 3,25 3,37 3,44 3,06 3,26 2,44 -1,05
Dividende8 0,75 0,80 0,84 0,88 0,92 0,92 0,62
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 27,940 Halten 15.736,85
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
13,43 16,65 0,82 11,25
KBV KCV KUV EV/EBITDA
0,83 3,53 0,71 8,48
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,92 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 31.07.2024 06.11.2024 20.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
6,41% 2,65% -0,46% 2,99%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE